Please see the Full Prescribing Information. Revcovi ® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. You are encouraged to report negative side effects of prescription drugs to the FDA. If you are pregnant or planning to become pregnant, or breastfeeding or planning to breastfeed, please talk to your doctor.The preferred treatment is bone marrow/stem cell transplantation. What is known about taking Revcovi during pregnancy? Restoration of a functional immune system is essential. If an ongoing decline in your blood’s measured adenosine deaminase (ADA) activity occurs, your immune function and clinical status will be monitored closely and precautions will be taken to help reduce your risk of infection. This monitoring will ensure you are maintaining appropriate levels for therapeutic benefit.While you are being treated with Revcovi, your doctor will need to do blood tests to monitor the levels of ADA activity and metabolites and overall immune function.Continuous therapy and adherence to the recommended drug schedule is important for the success of the treatment.What types of monitoring will be needed while I am taking Revcovi? Cancers of the immune system called lymphomas.Skin-related problems: redness and itching at the injection site.Blood and blood cell–related problems: red blood cells being destroyed faster than they can be made, resulting in anemia and higher or lower than normal number of platelets in the blood.Based on reports of side effects of other enzyme replacement therapies used to treat ADA-SCID, which are similar to Revcovi, patients taking Revcovi may also experience:.Cough and vomiting were the most common side effects reported by patients receiving Revcovi.What are the possible side effects of Revcovi? During this delay, it is important to be protected from exposure to infections until your immune system improves. There may be a delay in improvement of your immune system’s function after starting Revcovi treatment.Your doctor should not prescribe Revcovi if you have severely low blood platelet counts. Sub-Saharan Africa is the most affected part of the world (25.4 million cases, or 67 of all people living with HIV infection) central Asia and eastern Europe have experienced the largest increases in new HIV infections (47. recommendations for the use of the vaccine. In 2000, an estimated 37.7 million people were living with HIV infection globally. If you have lower than normal platelet counts, you may be at increased risk of bleeding at the injection site. This chapter includes information on: the coronavirus (COVID-19) vaccines.Important Safety Information Warnings and Precautions:
0 kommentar(er)
